← Back to headlines
Soligenix Advances CTCL Research with Positive Study Results
Soligenix (NASDAQ: SNGX) announced progress in its Cutaneous T-Cell Lymphoma (CTCL) research, reporting interim analysis and comparative study results.
18 Apr, 17:40 — 18 Apr, 17:40
Related Stories
New Israeli-led AI model predicts chemotherapy benefit in breast cancer
just now
Israeli researchers develop natural solutions for indoor air pollution
just now
Rat Poison Found in HiPP Baby Food in Austria, Police Suspect Blackmail
just now
Rat Poison Found in HiPP Baby Food Across Central Europe; Blackmail Suspected
just now